Core Viewpoint - Tongrentang is leveraging a multi-faceted strategic layout to enhance its performance in the health industry by extending its industrial chain, accelerating the transformation of scientific research results, and advancing digital transformation [1] Financial Performance - In Q1 2025, the company reported revenue of 5.276 billion yuan, a year-on-year increase of 0.16%, and a net profit attributable to shareholders of 582 million yuan, up 1.10% year-on-year [2] - The net cash flow from operating activities improved significantly from -252 million yuan in the same period last year to 833 million yuan, attributed to optimized raw material procurement and a more reasonable inventory structure [2] - Total assets reached 32.312 billion yuan, a 3.57% increase from the end of the previous year, while net assets attributable to shareholders grew by 4.38% [2] Product Development and Innovation - The company launched a new specification for the product "Angong Niuhuang Wan," focusing on both tradition and innovation to provide high-quality traditional Chinese medicine products [3] - Research efforts led to the completion of 11 quality standard studies and 4 efficacy studies on various traditional Chinese medicine products [2] Digital Transformation and Supply Chain Management - The year 2025 marks the beginning of the "Pharmaceutical Industry Digital Transformation Implementation Plan," which aims to enhance production efficiency and quality control through digital means [4] - Tongrentang is accelerating its digital transformation, focusing on supply chain management, production efficiency, and consumer services, with a commitment to transparency throughout the production and sales processes [4] - The company has implemented a traceability management system for traditional Chinese medicine, ensuring comprehensive supervision and openness across the entire industry chain [4] Technological Advancements - The upgraded Traditional Chinese Medicine Knowledge Graph System 3.0, integrated with the DeepSeek model, enhances the intelligent integration and interaction of TCM knowledge, significantly improving service capabilities [5] Policy Alignment and Long-term Growth - Tongrentang's long-term strategy aligns with national policies, particularly the ongoing "Healthy China" initiative and the revitalization of traditional Chinese medicine [6] - The company aims to achieve a control rate of 70% for key processes in the TCM industry by 2030, focusing on smart manufacturing and big data analysis [6] - The company demonstrates resilience and vitality as a time-honored TCM enterprise, with expectations for enhanced core competitiveness amid the digital transformation wave [7]

Group 1 - The signing ceremony for the "Clinical Research Project Cooperation between Jinan University and Zhongjing Wanshi Pharmaceutical" was successfully held, focusing on the integration of traditional Chinese medicine and modern medical research [3][5] - The project aims to explore the essence and regulatory mechanisms of "kidney deficiency syndrome" in elderly degenerative diseases, responding to the increasing prevalence of conditions such as osteoporosis, knee osteoarthritis, and Alzheimer's disease in an aging population [7][9] - Zhongjing Wanshi Pharmaceutical emphasizes the importance of high-quality medicinal materials and aims to innovate and modernize traditional Chinese medicine through this collaboration, which is seen as a significant step towards the internationalization of Chinese medicine [9] Group 2 - The expert team conducted multi-dimensional discussions on research proposals for kidney deficiency syndrome related to elderly osteoporosis, knee osteoarthritis, and Alzheimer's disease, under the leadership of key professors [9]

Core Viewpoint - The collaboration between Jinan University and Zhongjing Wanshi Pharmaceutical aims to conduct clinical research on age-related degenerative diseases, leveraging traditional Chinese medicine (TCM) to address conditions such as osteoporosis, knee osteoarthritis, and Alzheimer's disease, particularly focusing on the concept of kidney deficiency [4][6]. Group 1: Event Overview - The signing ceremony for the clinical research project was held on April 29, organized by Jinan University and attended by various experts and scholars from Guangdong [2]. - Key representatives included Zhang Ronghua, Vice President of Jinan University, and Ma Yun, Deputy General Manager of Zhongjing Wanshi Pharmaceutical, who signed the cooperation agreement [6]. Group 2: Research Focus - The project will explore the pathological mechanisms and key targets of age-related degenerative diseases, emphasizing the role of kidney deficiency in these conditions [6]. - The research aims to innovate TCM applications, particularly the modern use of classic formulas like Zuo Gui Wan and You Gui Wan, in treating kidney deficiency-related diseases [4][6]. Group 3: Collaborative Goals - The collaboration seeks to integrate multidisciplinary approaches to enhance the understanding and treatment of age-related diseases through TCM [6]. - Zhongjing Wanshi Pharmaceutical emphasizes the importance of high-quality medicinal materials and aims to explore new treatment pathways that combine TCM and Western medicine [6].